Breakthrough PTSD treatment achieves 68% remission rate in clinical trial
5 days ago
A newly FDA-cleared PTSD treatment uses personalized brain mapping and magnetic stimulation to target abnormal brain activity, with a clinical trial reporting a 52% reduction in symptoms and 68% remission. Researchers believe the technology could transform PTSD care and pave the way for more precise treatments for other mental health conditions.
phone_android📱 Use Epelcon on Your PhoneFaster. Always with you. Install the new Epelcon Mobile App v3.1.0 and access all 19 modules from your Android phone — Wallet, Jobs, Property, Diet Plans, Courses, Blog & more.Get the App
Advertise With Us!
Promote your brand, products or services across our homepage, shop, blog, email newsletters & social media channels.
This website uses cookies to enhance your browsing experience, serve personalized content, and analyze our traffic. By clicking “Accept”, you consent to our use of cookies.